Sino-U.S. To Jointly Set Up Medical Device R&D Base In Shenzhen
This article was originally published in PharmAsia News
Shenzhen Institute of Advanced Technology, a branch of the Chinese Academy of Sciences, and American medical device company STI Medical Systems will jointly set up a high-level medical device R&D base in Shenzhen. The collaboration will focus on five areas: (1) STI will invest in SIAT and set up the R&D facility; (2) STI and SIAT will jointly apply for research grants from the U.S. National Science Foundation, National Institutes of Health and the U.S. FDA; (3) SIAT may send its students for internships in the U.S; (4) both organizations will incorporate their funding, technology, talent and facilities as well as research management experience; and (5) both will establish an integrated industry application laboratory and possibly a joint venture firm when future conditions are ripe. (Click here for more - Chinese Language)
You may also be interested in...
Public Company Edition: Four health care special purpose acquisition vehicles went public and two others announced mergers, but only one biopharma firm priced an IPO during the week of 19-23 October. Replimune’s $250m offering led recent FOPOs.
Wholesalers are given three more years to set up electronic systems to verify saleable returns under another reprieve from the FDA. Yet the reprieve does not extend to manufacturers, who must respond within 24 hours to wholesalers’ requests to manually verify that a returned product is not suspect.
Agency explains how it will model vaccine authorization process on its licensing process for matters like inspections and lot release.